Kiek dividendų moka Shandong Weigao Group Medical Polymer Co 2024?
Pagal paskutinę informaciją nuo Spalis 2024, Shandong Weigao Group Medical Polymer Co per paskutinius 12 mėnesių mokėjo bendrą dividendą, kuris sudarė 0,25 CNY už akciją. Esant dabartiniam Shandong Weigao Group Medical Polymer Co kursui 4,65 CNY, tai atitinka 5,29 % dividendų grąžą.
Dividendai mokami kartus per metus.
5,29 % Dividendo grąža | = | 0,25 CNY Dividendas | 4,65 CNY akcijų kaina |
|
Ar Shandong Weigao Group Medical Polymer Co dividendai yra saugūs?
Shandong Weigao Group Medical Polymer Co kasmet didina dividendus jau 1 metus.
Per pastaruosius 10 metus Shandong Weigao Group Medical Polymer Co kasmet 14,777 % padidėjo.
Per 5 metų laikotarpį augo išmokos padidėjo 17,253 %.
Analitikai prognozuoja, kad einamaisiais verslo metais Dividendų didinimas bus 4,272%.
Shandong Weigao Group Medical Polymer Co Aktienanalyse
Ką daro Shandong Weigao Group Medical Polymer Co?
Shandong Weigao Group Medical Polymer Co Ltd is a globally operating company with headquarters in Weihai, China. It was founded in 1988 and has been listed on the Hong Kong Stock Exchange since 2004.
The company specializes in the production of medical polymer products and offers a wide range of products for various applications. Its business model is that of an integrated platform for research, development, manufacturing, and marketing of medical devices. Their customers include hospitals, medical practices, and distributors worldwide.
The company's portfolio includes products in the areas of infusion, blood transfusion, dialysis, surgery, anesthesia, first aid, and diagnostics. Both disposable and reusable products are available. With its offering, the company aims to contribute to improving the quality of healthcare and providing better outcomes for patients.
Shandong Weigao Group Medical Polymer Co Ltd is divided into three divisions: Medical Devices, Medical Consumables, and Biology. The Medical Devices division manufactures devices for use in anesthesia, surgery, resuscitation, and diagnostics. The Medical Consumables division includes products such as syringes, catheters, infusion and transfusion devices, disposable gloves, and wound dressings. The Biology division specializes in the development, manufacturing, and marketing of biopharmaceutical products, such as insulin.
The company's history is characterized by rapid expansion and continuous growth. The focus on R&D has played an important role in this. Through the use of advanced technologies, the company has acquired a multitude of patents in both China and other countries.
The company places a strong emphasis on quality assurance and has implemented a comprehensive quality control system. In addition, it aims to minimize its environmental impact and therefore operates according to the latest environmental standards.
In recent years, the company has established an international presence and opened subsidiaries in Europe and the USA. This demonstrates the company's desire to grow internationally and offer its products in more and more countries.
In summary, Shandong Weigao Group Medical Polymer Co Ltd is an innovative company specializing in the production of medical polymer products and biopharmaceutical products. It offers a wide range of products and is committed to a comprehensive quality control system and sustainability. With its international presence, the company aims to continue growing and offer its products worldwide. Shandong Weigao Group Medical Polymer Co yra viena populiariausių įmonių Eulerpool.com svetainėje.Akcijų taupymo planai siūlo patrauklią galimybę investuotojams ilgalaikėje perspektyvoje kurti turtą. Vienas pagrindinių privalumų yra vadinamasis vidutinės išlaidos efektas: reguliariai investuojant fiksuotą sumą į akcijas arba akcijų fondus, automatiškai perkama daugiau dalinių vertybių popierių, kai kainos yra žemos, ir mažiau – kai jos aukštos. Tai gali lemti palankesnę vidutinę dalies kainą per laiką. Be to, akcijų taupymo planai suteikia galimybę ir smulkiesiems investuotojams patekti į brangias akcijas, nes jie gali dalyvauti jau su mažomis sumomis. Reguliarus investavimas taip pat skatina disciplinuotą investavimo strategiją ir padeda išvengti emociškai pagrįstų sprendimų, pavyzdžiui, impulsyvaus pirkimo ar pardavimo. Be to, investuotojai gauna naudos iš potencialaus akcijų vertės augimo bei iš dividendų, kurie gali būti reinvestuoti, kas sustiprina sudėtinio palūkanų efektą ir taip skatina investuoto kapitalo augimą.